NCT07012109View on ClinicalTrials.gov

Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 5, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

July 31, 2028

Conditions
Polycythemia Vera
Interventions
DRUG

BEBT-507 Injection

The initial dose of BEBT-507 injection is 1.25mg/kg, administered subcutaneously at 1.25mg/kg, 2.5mg/kg, 5mg/kg, 10mg/kg or 15mg/kg every 12 weeks for two doses in total.

Trial Locations (1)

311100

Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

Sponsors

Lead Sponsor

BeBetter Med Inc
All Listed Sponsors
lead

BeBetter Med Inc

INDUSTRY